RxDoctor Payments DataLook up a doctor →

Wesley Bennett, MD

Interventional Cardiology · Meridian, MSNPI 1730166307

Payments from drug & device makers

$6,389in general payments, 2019–2025

Across 237 payments — averaging $26.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abiomed$1K
  • Novartis$1K
  • Pfizer$225
  • Celonova Biosciences, Inc.$217
  • Philips North America LLC$207
  • plus $1K from 26 others

What the payments were for

  • Travel & lodging$1,01116%
  • Food & beverage$5,36484%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,389 in reported general payments places this provider in the 30th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,405,613
Medicare patients
1,761
Services billed
14,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban664$618,571
XareltoRivaroxaban190$215,879
EntrestoSacubitril/Valsartan82$87,588
Repatha SureclickEvolocumab58$48,999
FarxigaDapagliflozin Propanediol54$47,108
BrilintaTicagrelor62$41,234
JardianceEmpagliflozin16$16,842
MultaqDronedarone Hcl13$12,077
OzempicSemaglutide11$11,068
Metoprolol Succinate815$10,921
Potassium Chloride321$8,342
Rosuvastatin Calcium454$6,383
Atorvastatin Calcium599$5,117
Ranolazine ErRanolazine59$5,067
Valsartan216$4,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$225$618,571664 claims
Johnson & JohnsonXarelto$115$215,879190 claims
AstraZenecaFarxiga, Brilinta$132$88,342116 claims
NovartisEntresto$1,135$87,58882 claims
Boehringer IngelheimJardiance$84$16,84216 claims
Sanofi-aventis U.S. LLCMultaq$11$12,07713 claims
Novo NordiskOzempic$12$11,06811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →